Author:
Nieva Reynaria,Achtchi Ahsan,Eapen Danny,Dollar Allen,Baer Jefferson,Mavromatis Kreton,Sperling Laurence
Reference66 articles.
1. Echocardiographic evaluation of cardiac resynchronization therapy: ready for routine clinical use?
2. Eagle KA, Lim MJ, Dabbous OH A validated prediction coronary artery disease. Circulation 2006;113:203-212. model for all forms of acute coronary syndrome: Estimating 10. Smith SC, Jr., Blair SN, Bonow RO et al. AHA/ACC Scienti c the risk of 6-month postdischarge death in an international Statement: AHA/ACC guidelines for preventing heart attack registry. JAMA 2004;291:2727-2733. and death in patients with atherosclerotic cardiovascular disease:2001update: A statement for healthcare profession- 27.Payne CD, Li YG, Small DS et al. Increased active metaboals from the American Heart Association and the American lite formation explains the greater platelet inhibition with College of Cardiology. Circulation2001;104:1577-1579. prasugrel compared to high-dose clopidogrel. J Cardiovasc
3. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel
4. Protective Effects of Aspirin against Acute Myocardial Infarction and Death in Men with Unstable Angina